BP-1-102 is primarily utilized in the field of cancer research due to its role as a potent and selective inhibitor of STAT3 (Signal Transducer and Activator of Transcription 3). This protein is often implicated in the growth and survival of various cancer cells, making BP-1-102 a valuable tool in studying and potentially disrupting tumor progression. Researchers employ it to investigate the mechanisms of STAT3 signaling pathways and to evaluate its efficacy in suppressing cancer cell proliferation. Additionally, it is explored for its potential in combination therapies, where it may enhance the effects of other anticancer drugs. Its application extends to preclinical studies aimed at developing targeted treatments for cancers that are driven by aberrant STAT3 activity.